Share
  • Facebook
  • Twitter
  • Linked In
  • Google+
back top

1300 members from 70 countries Join ICRS

News

BEDFORD, Mass.–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that regulatory authorities in Australia granted approval to MONOVISC®, Anika’s single injection viscosupplement for the treatment of pain associated with osteoarthritis of all synovial joints, including the hip and knee. 

Anika Announces Regulatory Approval for MONOVISC® in Australia

Anika Announces Regulatory Approval for MONOVISC® in Australia

20/10/2017